Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real -World Setting in Spain: The Venares Study

Introduction: The BCL-2 inhibitor venetoclax (Ven) has been approved on monotherapy or combined with rituximab in relapsed/refractory CLL patients (pts) and combined with obinutuzumab in previously untreated CLL pts. However, evidence from clinical trials can be difficult to generalize to real-world...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2021-11, Vol.138 (Supplement 1), p.1561-1561
Hauptverfasser:	Baltasar, Patricia, Terol, María José, Marquet Palomanes, Juan, Ramírez Payer, Angel, Moreno, Carol, Osorio, Santiago, De la Cruz, Fátima, Garcia-Marco, Jose A., Ortiz, Macarena, Ríos Herranz, Eduardo, Magnano, Laura, Iraheta, Sandra, Puerta, Jose Manuel, de la Serna, Javier, Smucler Simonovich, Alicia, Arguiñano, Jose Maria, Loscertales, Javier, Muiña, Begoña, Fernandez, Ruben, García, Tomas, Márquez, José A., Muntañola Prat, Ana, Pérez Persona, Ernesto, Yáñez, Lucrecia, Pérez-Encinas, Manuel, González Díaz, Marcos, Caballero, Gonzalo, Andreu, María Angeles, Andreu, Rafael, Ruiz-Zorrilla, Ana, Moreno, Diana, Ferrà, Christelle
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!